Pharmosa Biopharm Inc.

Pharmosa Biopharm is a biotechnology company based in Taipei, Taiwan, focused on the development of innovative drug delivery systems, particularly in the fields of pulmonary vascular and rare diseases. The company leverages proprietary liposomal formulations and manufacturing technology to create drug-device combination products, including next-generation smart-technology nebulizers designed for home-based therapies. Pharmosa operates with a strategy of regional and global partnerships to commercialize its pipeline through 505(b)(2) or hybrid regulatory pathways. Their primary focus is on expanding the clinical potential of existing drugs by enhancing delivery formulations, with a significant emphasis on inhaled therapies for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).